生白合剂治疗肿瘤化疗导致骨髓抑制疗效的Meta分析
|
摘要
目的系统评价生白合剂治疗肿瘤化疗后骨髓抑制的临床疗效,为临床用药提供参考。方法通过系统检索中国学术期刊网全文数据库、万方数据库以及维普中文医学生物期刊发表的文献,收集生白合剂治疗恶性肿瘤化疗后骨髓抑制疗效的临床研究文献,采用Rev Man 5. 0版软件进行Meta分析。结果共纳入7篇临床研究文献,合计3310例患者。Meta分析结果显示,生白合剂治疗肿瘤化疗后骨髓抑制有明显临床疗效(OR=9. 36,95%CI:7. 82～11. 20,P <0. 001);亚组分析显示,生白合剂疗程9天(OR=10. 06,95%CI:8. 35～12. 13,P <0. 001)或14天(OR=4. 19,95%CI:2. 18～8. 06,P <0. 001)的临床疗效均优于服用生白合剂至化疗中断或停止;两种疗效评价标准下生白合剂均能有效治疗肿瘤化疗后骨髓抑制(OR=8. 12,95%CI:6. 66～9. 91,P <0. 001; OR=6. 42,95%CI:4. 52～9. 12,P <0. 001)。结论生白合剂治疗恶性肿瘤化疗后骨髓抑制有明显的临床疗效,使用安全且无明显毒副作用。
Objective To analyze the clinical efficacy of Shengbai mixture in the treatment of bone marrow suppression after chemotherapy for malignant tumors,and to provide reference for clinical medication. Methods The literatures of Chinese academic journal network full-text database,Wanfang database and Weipu Chinese medical journal were systematically searched,and the clinical research literature on the efficacy of Shengbai mixture in the treatment of bone marrow suppression after chemoradiotherapy for malignant tumors was studied. Meta-5. 0 software was used for meta-analysis. Results A total of 7 articles were included,and the cumulative number of trials was 3310. The meta-analysis showed that the effect of Shengbai mixture on bone marrow suppression after chemotherapy was significant( OR = 9. 36,95% CI: 7. 82-11. 20,P < 0. 001). Subgroup analysis showed that the clinical efficacy of Shengbai mixture for 9 days or 14 days was better than that of taking Shengbai mixture until interruption or discontinuation of chemotherapy( OR = 10. 06,95% CI: 8. 35-12. 13,P < 0. 001; OR = 4. 19,95% CI: 2. 18-8. 06,P < 0. 001). Two evaluation criteria of therapeutic effect showed that Shengbai mixture could effectively treat bone marrow suppression after chemotherapy for cancer( OR = 8. 12,95%CI: 6. 66-9. 91,P < 0. 001; OR = 6. 42,95% CI: 4. 52-9. 12,P < 0. 001). Conclusion Shengbai mixture has obvious effect on bone marrow suppression after chemotherapy for malignant tumors. It is safe in clinical use and has no obvious side effects.
Objective To analyze the clinical efficacy of Shengbai mixture in the treatment of bone marrow suppression after chemotherapy for malignant tumors,and to provide reference for clinical medication. Methods The literatures of Chinese academic journal network full-text database,Wanfang database and Weipu Chinese medical journal were systematically searched,and the clinical research literature on the efficacy of Shengbai mixture in the treatment of bone marrow suppression after chemoradiotherapy for malignant tumors was studied. Meta-5. 0 software was used for meta-analysis. Results A total of 7 articles were included,and the cumulative number of trials was 3310. The meta-analysis showed that the effect of Shengbai mixture on bone marrow suppression after chemotherapy was significant( OR = 9. 36,95% CI: 7. 82-11. 20,P < 0. 001). Subgroup analysis showed that the clinical efficacy of Shengbai mixture for 9 days or 14 days was better than that of taking Shengbai mixture until interruption or discontinuation of chemotherapy( OR = 10. 06,95% CI: 8. 35-12. 13,P < 0. 001; OR = 4. 19,95% CI: 2. 18-8. 06,P < 0. 001). Two evaluation criteria of therapeutic effect showed that Shengbai mixture could effectively treat bone marrow suppression after chemotherapy for cancer( OR = 8. 12,95%CI: 6. 66-9. 91,P < 0. 001; OR = 6. 42,95% CI: 4. 52-9. 12,P < 0. 001). Conclusion Shengbai mixture has obvious effect on bone marrow suppression after chemotherapy for malignant tumors. It is safe in clinical use and has no obvious side effects.
引文
[1]周春花,陈功,曾亮,等.生白合剂对肺癌化疗后骨髓抑制的疗效观察[J].中国中西医结合外科杂志,2018,24(2):131-134.
[2]陈城,乐涵波,张斌杰,等.生白口服液治疗非小细胞肺癌化疗后白细胞减少58例疗效观察[J].中国中医药科技,2013,20(5):529-530.
[3]邵玉英,马玉静.生白口服液治疗放化疗致白细胞减少症[J].中医杂志,2000,41(4):207.
[4]林红生,邵静,王秀娥,等.生白口服液治疗放化疗致白细胞减少症的临床观察[J].中华中医药杂志,1997,12(6):59-60.
[5]马加斌,徐化卿.生白宝预防化疗所致白细胞减少症60例[J].河南中医药学刊,1995,10(5):46-47.
[6]邵玉英.生白宝治疗放化疗致白细胞减少症的临床及实验研究[J].中医学报,1996,11(6):32-35.
[7]何清清.生白宝口服液预防联合化疗所致白细胞下降疗效观察[J].中医学报,1995,10(3):46.
[8]肖立新,姜长林.生白宝口服液治化疗所致白细胞减少的随机对照观察[J].河南中医药学刊,1994,9(4):8-10.
[9]黄慧琳,谢美莺.生白口服液治疗化疗患者白细胞减少症的研究[J].海峡药学,2003,15(3):54-54.
[10]李冰雪,袁嘉萌,郑佳彬,等.生白口服液防治放化疗后白细胞减少症研究概况[J].中华中医药杂志,2018,33(4):1455-1458.
[11]林能明,陈晓钟.生白宝口服液治疗恶性肿瘤放、化疗引起的白细胞减少症临床疗效观察[J].肿瘤防治研究,1995,22(6):392-393.
[2]陈城,乐涵波,张斌杰,等.生白口服液治疗非小细胞肺癌化疗后白细胞减少58例疗效观察[J].中国中医药科技,2013,20(5):529-530.
[3]邵玉英,马玉静.生白口服液治疗放化疗致白细胞减少症[J].中医杂志,2000,41(4):207.
[4]林红生,邵静,王秀娥,等.生白口服液治疗放化疗致白细胞减少症的临床观察[J].中华中医药杂志,1997,12(6):59-60.
[5]马加斌,徐化卿.生白宝预防化疗所致白细胞减少症60例[J].河南中医药学刊,1995,10(5):46-47.
[6]邵玉英.生白宝治疗放化疗致白细胞减少症的临床及实验研究[J].中医学报,1996,11(6):32-35.
[7]何清清.生白宝口服液预防联合化疗所致白细胞下降疗效观察[J].中医学报,1995,10(3):46.
[8]肖立新,姜长林.生白宝口服液治化疗所致白细胞减少的随机对照观察[J].河南中医药学刊,1994,9(4):8-10.
[9]黄慧琳,谢美莺.生白口服液治疗化疗患者白细胞减少症的研究[J].海峡药学,2003,15(3):54-54.
[10]李冰雪,袁嘉萌,郑佳彬,等.生白口服液防治放化疗后白细胞减少症研究概况[J].中华中医药杂志,2018,33(4):1455-1458.
[11]林能明,陈晓钟.生白宝口服液治疗恶性肿瘤放、化疗引起的白细胞减少症临床疗效观察[J].肿瘤防治研究,1995,22(6):392-393.